Navigation Links
Whooping cough vaccine antigen disappearing from bacteria in US
Date:12/12/2013

Vaccines for whooping cough contain three to five protective antigens, the presence of which are critical to the vaccine's effectiveness. But one of the antigens, pertactin, which had been present in almost all isolates of Bordetella pertussis in the US as late as 2010, is now absent from more than half of them, according to a paper published ahead of print in Clinical and Vaccine Immunology.

"These findings tell us that there is an evolutionary advantage to lacking the protein that may have important vaccine implications," says first author Lucia C. Pawloski, of the Centers for Disease Control and Prevention, Atlanta, GA.

In the study, the researchers screened 1,300 isolates dating from 1935-2012, obtained from outbreak and surveillance studies. They used polymerase chain reaction (PCR) to identify DNA insertions into the pertactin gene, which prevents expression of that gene. The earliest such isolate was from 1994, and the next, 2010. There were 267 such isolates.

Thanks to the vaccine's other antigens, the vaccine remains effective, but that does not mean public health authorities should be complacent.

"This recent and drastic change in response to a particular vaccine antigen highlights the need to continue monitoring the circulating bacterial population to allow us to better predict future potential vaccine antigens and respond to the recent upsurge in pertussis," says Pawloski.

It is particularly important that pregnant women be vaccinated against pertussis, since infants are at greatest risk for having severe, potentially life-threatening complications from pertussis.

"After receiving this vaccine, a pregnant woman's body creates protective antibodies and passes some of them to her baby before birth," says Pawloski.

Those antibodies provide the baby with some protection that lasts until it is old enough to be vaccinated. However, fewer than 10 percent
'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Pneumonia revealed in a cough
2. Queens scientists seek vaccine for Pseudomonas infection
3. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. SFU HIV/AIDS vaccine research gets financial boost
6. Researchers identify Achilles heel of dengue virus, target for future vaccines
7. AAPS National Biotechnology Conference to highlight innovative vaccines
8. Army study: DNA vaccine and duck eggs protect against hantavirus disease
9. Sensitive test helps improve vaccine safety
10. Overweight? Theres a vaccine for that
11. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Oct. 16, 2012  Today 23andMe, the leading personal ... as Vice President Communications, Neil Rothstein as Vice ... Strategic Alliances joining the company,s executive leadership team. ... Castro is responsible for the company,s corporate communications, ...
... MedNet Solutions, a global life sciences technology solutions ... & Data Corporation (SDC), a specialized Contract Research Organization ... services to the life sciences industry, are pleased to ... ™ EDC platform as their eClinical ...
... MOUNTAIN VIEW, Calif. and RAANANA, Israel, Oct. 23, ... ), the leading licensor of silicon intellectual property ... Ltd, a global supplier of embedded speech processing ... deliver enhanced speech processing solutions for smart devices, ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 2CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 3
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... SAN DIEGO, July 24, 2008 NuVasive, Inc.,(Nasdaq: ... on developing products for,minimally disruptive surgical treatments for ... previously announced acquisition of the Osteocel,biologics business from ... $35,million in cash, plus additional milestone-based contingent payments ...
... Calif., July 24 Abaxis, Inc.,(Nasdaq: ABAX ), a ... results for the first,fiscal quarter ended June 30, 2008., ... up 7% over last year,s comparable quarter. -- Total ... 127 units or 19% over last ...
... physicians, pulmonary and critical care clinicians, ... overuse of antibiotics, DURHAM, N.C., July 24 ... of the American Thoracic Society and,Society of Hospital ... physicians, and researchers are unanimous in their view ...
Cached Biology Technology:NuVasive Completes Acquisition of Osteocel Biologics Business 2NuVasive Completes Acquisition of Osteocel Biologics Business 3NuVasive Completes Acquisition of Osteocel Biologics Business 4NuVasive Completes Acquisition of Osteocel Biologics Business 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 8U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... for 10 separate biopanning experiments, complexity ... gIII Sequencing Primer (100 pmol), for ... Primer (100 pmol), for automated DNA ... Control target (Streptavidin) and Elutant (Biotin), ...
... Materials for 15-20 enhancements when used as ... Blot Signal Enhancement System is designed to amplify the ... excellent tool for evaluating proteins with low expression., ... membrane prior to blocking the membrane; 1x solution; 250 ...
Biology Products: